521 related articles for article (PubMed ID: 28755058)
1. Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
Chen Z; Gong Y; Shi Y
Clin Drug Investig; 2017 Oct; 37(10):891-899. PubMed ID: 28755058
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
5. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of emerging immunotherapies in psoriasis.
Yiu ZZ; Warren RB
Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
[TBL] [Abstract][Full Text] [Related]
7. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
8. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
Tonini A; Gualtieri B; Panduri S; Romanelli M; Chiricozzi A
Expert Opin Biol Ther; 2018 Feb; 18(2):135-148. PubMed ID: 29103330
[TBL] [Abstract][Full Text] [Related]
9. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
10. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
11. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.
Campa M; Mansouri B; Warren R; Menter A
Dermatol Ther (Heidelb); 2016 Mar; 6(1):1-12. PubMed ID: 26714681
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in psoriasis: a systematic review.
Lee EB; Amin M; Bhutani T; Wu JJ
Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 antagonists in the treatment of psoriasis.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2015; 19(2):109-14. PubMed ID: 25775627
[TBL] [Abstract][Full Text] [Related]
14. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
15. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Yang K; Oak ASW; Elewski BE
Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
[TBL] [Abstract][Full Text] [Related]
16. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
[TBL] [Abstract][Full Text] [Related]
17. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]